The relationship of dyspnoea to function and quality of life in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 67, Issue 5, 2008, Pages 644-650

  Baron, M ^a,k   Sutton, E ^b   Hudson, M ^a   Thombs, B ^a   Markland, J ^c   Pope, J ^d   Robinson, D ^e   Jones, N ^f   Docherty, P ^g   Abu Hakima, M ^h   LeClercq, S ^h   Smith, D ⁱ   Mathieu, J P ^j  

^a MCGILL UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g MONCTON HOSPITAL   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; DISABILITY EVALUATION; DYSPNEA; FEMALE; HEALTH STATUS; HUMANS; HYPERTENSION, PULMONARY; LINEAR MODELS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; VITAL CAPACITY;

EID: 42449141440     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.075721     Document Type: Article

References (35)

1. Launay D, Hachulla E, Hatron PY, Michon-Pasturel U, Hebbar M, Queyrel V, et al. Pulmonary hypertension screening in systemic scleroderma: a cohort study of 67 patients (in French). Rev Med Interne 2001;22:819-29.
2. Racz H, Mehta S. Dyspnea due to pulmonary hypertension and interstitial lung disease in scleroderma: room for improvement in diagnosis and management. J Rheumatol 2006;33:1723-5.
3. Mehta S, Little S. Screening for pulmonary hypertension in scleroderma: how and when to look? J Rheumatol 2006;33:204-6.
4. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003;29:371-90.
5. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28:759-67.
6. Spagnolatti L, Zoia MC, Volpini E, Convertino G, Fulgoni P, Corsico A, et al. Pulmonary function in patients with systemic sclerosis. Monaldi Arch Chest Dis 1997;52:4-8.
7. Ullman S, Halberg P, Wiik A, Jacobsen S. Scleroderma - systemic sclerosis. Serology, lung function and survival. Ugeskr Laeger 1999;161:3084-90.
8. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283- 9.
9. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
10. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
11. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
12. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123:185-9.
13. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
14. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
15. Lareau SC, Meek PM, Roos PJ. Development and testing of the modified version of the pulmonary functional status and dyspnea questionnaire (PFSDQ-M). Heart Lung 1998;27:159-68.
16. Lareau SC, Carrieri-Kohlman V, Janson-Bjerklie S, Roos PJ. Development and testing of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ). Heart Lung 1994;23:242-50.
17. World Hearth Organization. International classification of functioning, disability, and health. 2nd edn. Geneva, Switzerland: World Health Organization, 2001.
18. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21(3 Suppl 29):S42-6.
19. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001;60:1117-22.
20. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
21. Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003;30:1782-7.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. Paula S, Correia D, Morgado R, Fernandes D, Serrador A, Marques A, et al. Correlation between dyspnea and lung function evaluated by spirometry and body plethysmography in COPD patients. Rev Port Pneumol 2005;11(6 Suppl 1):22-3.
24. Grazzini M, Scano G, Foglio K, Duranti R, Bianchi L, Gigliotti E, et al. Relevance of dyspnoea and respiratory function measurements in monitoring of asthma: a factor analysis. Respir Med 2001;95:246- 50.
25. Droszcz W, Doboszynska A, Pleger E, Rasche K, Nowak U, Rausch V, et al. Dyspnea and lung function. Results of a multicenter study. Pneumologie 1998;52:389-95.
26. Vivodtzev I, Pepin JL, Votteto G, Mayer V, Porsin B, Levy P, et al. Improvement in quadriceps strength and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD. Chest 2006;129:1540-8.
27. Weiner P, Gross D, Meiner Z, Ganem R, Weiner M, Zamir D, et al. Respiratory muscle training in patients with moderate to severe myasthenia gravis. Can J Neurol Sci 1998;25:236-41.
28. Sahebjami H. Dyspnea in obese healthy men. Chest 1998;114:1373-7.
29. Eiser N, West C, Evans S, Jeffers A, Quirk F. Effects of psychotherapy in moderately severe COPD: a pilot study. Eur Respir J 1997;10:1581-4.
30. Calikoglu M, Sahin G, Yazici AE, Yazici K, Ozisik S. Pulmonary muscle strength, pulmonary function tests, and dyspnea in women with major depression. J Womens Health (Larchmt) 2004;13:93-8.
31. American College of Chest Physicians (AAoCaPR). Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. J Cardiopulm Rehabil 1997;17:271-405.
32. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995;273:59-65.
33. Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Henstorf GH, et al. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol 2007;34:359-67.
34. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007;56:1676-84.
35. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.